8-K: Alkermes Terminates VIVITROL Authorized Generic Agreement

Alkermes plc announced the termination of its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals LLC for a generic version of VIVITROL, effective July 6, 2026.

Summary

• Alkermes plc and Amneal Pharmaceuticals LLC have terminated their Authorized Generic Product Supply Agreement concerning an authorized generic version of VIVITROL (naltrexone for extended-release injectable suspension).
• The agreement, originally entered into on September 9, 2025, was set to run for one year starting from a Third Party ANDA Product Launch.
• Under the agreement, Alkermes Pharma Ireland Limited (APIL) would supply Amneal with the authorized generic product at a premium to manufacturing cost, plus a share of net profits.
• The termination occurred after Alkermes notified Amneal of unmet terms, and Amneal subsequently chose not to order any batches.
• No penalties were incurred by Alkermes due to the termination, and neither party owes further payments or obligations.
• Both companies have released all claims against each other related to the agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While the termination itself is not positive, the absence of penalties and mutual release of claims mitigates potential negative financial or legal repercussions.

Positives

• No penalties were incurred by Alkermes plc in connection with the termination.
• No further payments or obligations are owed by either Alkermes or Amneal under the terminated agreement.
• Both parties have mutually released all claims against each other, simplifying future relations.

Negatives

• The authorized generic product supply agreement with Amneal Pharmaceuticals LLC has been terminated, indicating a disruption in the planned distribution of a generic VIVITROL.
• Amneal Pharmaceuticals LLC did not wish to order any batches under the agreement, suggesting a lack of commercial interest or viability from their perspective.

Risks

• The termination of the agreement may impact the availability or market penetration strategy for an authorized generic version of VIVITROL.
• The underlying reasons for Amneal not meeting certain terms of the agreement could indicate potential challenges in the market for this specific product.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on the termination of a material definitive agreement.

Industry Context

StockSavvy.ai notes that the termination of this agreement suggests potential challenges in the market for authorized generics or a strategic shift by Alkermes regarding its VIVITROL product line. The company's ability to secure and maintain such supply agreements is crucial for its revenue diversification and market share protection strategies.

Stakeholder Impact

• Shareholders: The termination may lead to a reassessment of Alkermes' strategy for VIVITROL and its authorized generic program, potentially impacting future revenue streams from this product.
• Customers: The availability and pricing of VIVITROL and its potential generic versions may be affected, although the immediate impact is unclear without further market analysis.
• Suppliers: Suppliers involved in the manufacturing of VIVITROL or the authorized generic product may see changes in demand based on Alkermes' revised strategy.

Next Steps

• Alkermes plc will continue to manage its VIVITROL product line without the authorized generic distribution through Amneal Pharmaceuticals LLC.
• Both Alkermes and Amneal will proceed with their respective business operations, having resolved all claims related to the terminated agreement.

Key Dates

Keywords

Alkermes, Amneal Pharmaceuticals, VIVITROL, naltrexone, authorized generic, product supply agreement, termination, Form 8-K, drug manufacturing, pharmaceuticals